Defunct Company
Total Trials
3
As Lead Sponsor
As Collaborator
0
Total Enrollment
92
NCT01428596
Safety and Immunogenicity of HIVAX in HIV-1 Infected Subjects
Phase: Phase 1
Role: Lead Sponsor
Start: Sep 30, 2010
Completion: Dec 31, 2020
NCT04428073
Therapeutic Vaccine Trial of COVID-19 for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection
Start: Jul 31, 2020
Completion: Dec 31, 2021
NCT04318379
Therapeutic Hepatitis C Virus Vaccine
Start: Apr 20, 2021
Completion: Dec 31, 2023